Seres Therapeutics (MCRB) reported second-quarter 2026 net income of $4.6 million, compared with a net loss of $19.9 million in the year-earlier period. Total revenue was $736,000, and basic and diluted net income per share were both $0.47.
The company said the quarter included a $25 million gain on the sale of the VOWST business tied to a milestone termination payment from Nestlé Health Science. Seres also announced further facility cost reductions and said its available cash resources are expected to fund operations through the first quarter of 2027.
- Cash and cash equivalents were $15.6 million as of June 30, 2026.
- Research and development expenses were $9.1 million, down from $12.9 million a year earlier.
- General and administrative expenses were $7.1 million, down from $10.3 million a year earlier.
- Seres said 12 of 15 participants, or 80%, achieved an immunosuppressive-free clinical response at day 15 in an investigator-sponsored SER-155 trial in irEC.
- The company entered an agreement to terminate its 200 Sidney Street lease early, with accounting for the transaction to be reported in third-quarter 2026 results.
$MCRB Hedge Fund Activity
We have seen 13 institutional investors add shares of $MCRB stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 74,590 shares (-41.5%) from their portfolio in Q1 2026, for an estimated $661,613
- 683 CAPITAL MANAGEMENT, LLC removed 52,314 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $464,025
- AMERICAN CENTURY COMPANIES INC added 46,045 shares (+283.0%) to their portfolio in Q1 2026, for an estimated $408,419
- CITADEL ADVISORS LLC removed 31,418 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $278,677
- SCHONFELD STRATEGIC ADVISORS LLC removed 29,097 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $258,090
- VONTOBEL HOLDING LTD. added 19,741 shares (+19.1%) to their portfolio in Q2 2026, for an estimated $155,756
- MARSHALL WACE, LLP added 19,362 shares (+16.1%) to their portfolio in Q1 2026, for an estimated $171,740
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
